If metformin is administered early, in the initial phase of symptoms, the risk reduction for hospitalization and death is reduced to 50%.
THE metformina widely prescribed diabetes drug, reduces at least 40% the likelihood that a patient with Covid-19 will need hospitalization and die, while the reduction in risk exceeds 50% if the drug is given early in the initial phase of symptoms, shows a new -double-blind, randomized and placebo-controlled- phase 3 clinical trial in the US, according to the researchers.
The scientists, led by the assistant professor Caroline Bramante of the University of Minnesota School of Medicine, who made the relevant publication in the American medical journal “New England Journal of Medicine”, studied 1,323 adults aged 30-85 (mean age 46) who were all overweight or obese (with a body mass index above of 25), including pregnant women (6%), as well as both vaccinated (most) and unvaccinated.
See the scientific publication here
The patients were randomly divided into different groups and received either only metformin (anti-diabetic), or only ivermectin (parasiticide), or only fluvoxamine (antidepressant) – three drugs for other diseases but with possible activity against the coronavirus – or a combination of the above drugs, or a placebo.
“Our study showed that metformin can reduce the likelihood that a patient will need to visit a hospital emergency department or be hospitalized because of Covid-19,” said Dr. Bramante. In contrast, no positive effect was found from the administration of either ivermectin or fluvoxamine. On the other hand, none of the three drugs (not even metformin) prevented hypoxemia (decreased oxygen in the blood).
RES-EMP
Read the News today and get the latest news. Follow us on Google News and be the first to learn all the news from Skai.gr.
